As a highly selective inhibitor of AURKB, AZD1152 can overcome resistance to EGFR inhibitors in lung cancer via enhancing apoptosis, modulate paclitaxel response in non–small cell lung cancer, and enhance chemotherapeutic efficacy in pancreatic and colon cancers (15, 16, 24). Here, AURKB is linked to malignant colon neoplasm.